COL1A1 and idiopathic pulmonary fibrosis: For this reason, drug screening often includes a pre-treatment with recombinant TGF-β to activates the IPF fibroblasts and enhance the expression of the profibrotic markers ACTA2, COL1A1, and Fibronectin.